IPO UPDATE: Bubble worries heighten after another big Alzheimer's offering
This article was originally published in Scrip
Which is a bigger sign of a biotech bubble: NantKwest launching an initial public offering as the highest-value development-stage company to ever go public in the US or vTv Therapeutics raising more than $100m in an IPO to support another Alzheimer's drug candidate that was rejected by big pharma?
You may also be interested in...
Intellia Therapeutics Inc. sold more shares in its initial public offering than originally expected and the CRISPR/Cas9 specialist did so at the top of its proposed price range, proving that investors remain excited about gene editing, but have less enthusiasm for other early-stage therapeutics firms.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.